CAR-T: How far have we come and where are we going?

In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days. Parexel’s experts Mo Heidaran, Alexander Gee and host Alberto Grignolo, all part of our newly-integrated Regulatory & Access consulting unit, also weigh in on the current regulatory and reimbursement landscape for CAR-T and what we might look forward to in the future for this and other cell and gene therapies.

Previous Article
Bioprocessing and Biologics risk from Coronavirus
Bioprocessing and Biologics risk from Coronavirus

Coronavirus COVID-19 has been all over the news recently.  This virus is part of a larger family called Cor...

Next Article
How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance
How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance

The UK national health technology assessment (HTA) body, the National Institute for Health and Clinic...

×

Let's start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!